CTOs on the Move

AlloSource

www.allosource.org

 
AlloSource is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Centennial, CO. To find more information about AlloSource, please visit www.allosource.org
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Brian Hobbs
Director of IT Profile

Similar Companies

DeRoyal Industries, Inc.

DeRoyal manufactures quality healthcare products worldwide. DeRoyal is behind everything from the number one orthopedic hospital brand to online tools that power the medical industry. We keep innovating because it's part of our heritage.

Preston Memorial Hospital

Preston Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Preston Memorial Hospital is based in Kingwood, WV. You can find more information on Preston Memorial Hospital at www.prestonmemorial.org

Circle Cardiovascular Imaging

Circle Cardiovascular Imaging is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Western Kentucky Regional Blood Center

Western Kentucky Regional Blood Center is a Owensboro, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.